• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and diagnostic laboratory immunology >Humoral Immune Response to Human Cytomegalovirus in Patients Undergoing Percutaneous Transluminal Coronary Angioplasty
【24h】

Humoral Immune Response to Human Cytomegalovirus in Patients Undergoing Percutaneous Transluminal Coronary Angioplasty

机译：经皮腔内冠状动脉成形术患者对人巨细胞病毒的体液免疫反应

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Possible causal relations between prior human cytomegalovirus (HCMV) infection and atherosclerosis and between HCMV reactivation and restenosis after coronary angioplasty have been suggested. We investigated patterns of antibodies directed to HCMV in 112 patients undergoing percutaneous transluminal coronary angioplasty (PTCA) and in a group of sex- and age-matched controls (blood donors without evidence of atherosclerosis). Levels of antibodies to HCMV were measured by enzyme-linked immunosorbent assay (ELISA) of serum samples drawn before and 5 weeks after PTCA. To further differentiate the humoral immune response, we specifically tested antibody reactivity towards four single HCMV proteins (IE2, p52, pp150, and pp65) by recombinant ELISAs. We found that 73% of PTCA patients and 69% of sex- and age-matched controls were seropositive for HCMV (odds ratio, 1.2 [not significant]). The corresponding odds ratios for matched pairs ranged in the recombinant ELISAs from 1.2 to 1.4. Patients had more often high titers of anti-HCMV antibodies (11 versus 4%; odds ratio = 3.3 [0.9 to 15.2]; P = 0.052) and high titers of anti-pp150 antibodies (13 versus 4%; odds ratio = 6.0 [1.3 to 38.8]; P = 0.008). Anti-HCMV immunoglobulin M antibodies were not detected in any patient. There was no evidence of acute HCMV reactivation after PTCA, since the titers of antibodies to the investigated recombinant proteins did not increase at 5 weeks after PTCA. Our results show a limited association between prior HCMV infection and coronary artery disease. We infer that positive anti-HCMV titers are not a major risk factor at the time of disease manifestation. However, this study cannot rule out a possible role of HCMV at earlier stages of the atherosclerotic process. Recombinant ELISAs provide a valuable tool for investigating the antiviral immune response.
机译：已经提出了先前的人类巨细胞病毒（HCMV）感染与动脉粥样硬化之间以及冠状动脉成形术后HCMV活化与再狭窄之间可能的因果关系。我们调查了112例行经皮腔内冠状动脉成形术（PTCA）的患者以及一组性别和年龄相匹配的对照（无动脉粥样硬化证据的献血者）中针对HCMV的抗体模式。通过PTCA之前和5周后抽取的血清样品的酶联免疫吸附测定（ELISA）测量HCMV抗体水平。为了进一步区分体液免疫反应，我们通过重组ELISAs具体测试了针对四种单一HCMV蛋白（IE2，p52，pp150和pp65）的抗体反应性。我们发现73％的PTCA患者和69％的性别和年龄相匹配的对照者对HCMV呈血清阳性（比值比为1.2，[无显着性]）。重组ELISA中匹配对的对应比值比在1.2至1.4之间。患者更常出现高滴度的抗HCMV抗体（11对4％;比值比= 3.3 [0.9至15.2]; P = 0.052）和高滴度的抗pp150抗体（13对4 ％;比值比= 6.0 [1.3至38.8]; P = 0.008）。在任何患者中均未检测到抗HCMV免疫球蛋白M抗体。 PTCA后没有急性HCMV重新活化的证据，因为在PTCA后5周，针对所研究的重组蛋白的抗体滴度没有增加。我们的结果表明，先前的HCMV感染与冠状动脉疾病之间的关联有限。我们推断抗HCMV阳性滴度在疾病表现时不是主要的危险因素。但是，这项研究不能排除HCMV在动脉粥样硬化过程早期的可能作用。重组ELISA为研究抗病毒免疫反应提供了有价值的工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号